Literature DB >> 9145898

Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae.

Y S Kim1, Q Liu, L L Chow, M G Täuber.   

Abstract

The fluoroquinolone trovafloxacin was bactericidal (0.47 +/- 0.23 delta log10 CFU/ml x h after 10 mg/kg of body weight and 0.78 +/- 0.15 delta log10 CFU/ml x h after 30 mg/kg) in the treatment of experimental meningitis caused by a highly penicillin-resistant (MIC and minimum bactericidal concentration = 4 and 4 microg/ml) strain of Streptococcus pneumoniae. Combinations with ampicillin and rifampin were indifferent compared to single drugs.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9145898      PMCID： PMC163879     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Worldwide increase in pneumococcal antibiotic resistance.

Authors:  K P Klugman; H J Koornhof
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

2.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; S Kunz; O Zak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae.

Authors:  M G Täuber; C A Doroshow; C J Hackbarth; M G Rusnak; T A Drake; M A Sande
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

Review 4.  Quinolone therapy for infections of the central nervous system.

Authors:  W M Scheld
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

5.  Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  I R Friedland; M Paris; S Ehrett; S Hickey; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

7.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

9.  Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study.

Authors:  W F Schlech; J I Ward; J D Band; A Hightower; D W Fraser; C V Broome
Journal:  JAMA       Date:  1985 Mar 22-29       Impact factor: 56.272

10.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191
View more
  18 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.

Authors:  P Cottagnoud; F Acosta; M Cottagnoud; K Neftel; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  D Rodoni; F Hänni; C M Gerber; M Cottagnoud; K Neftel; M G Täuber; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 4.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

5.  Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxaxin and ceftriaxone with or without vancomycin.

Authors:  Allan R. Tunkel
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

6.  Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Authors:  Keith M Olsen; Martha Gentry-Nielsen; Mei Yue; Mary U Snitily; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.

Authors:  D P Nicolau; P R Tessier; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

9.  Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.

Authors:  Y S Kim; Q Liu; L L Chow; H F Chambers; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.

Authors:  Marc Pfister; Liping Zhang; Margareta Hammarlund-Udenaes; Lewis B Sheiner; Cynthia M Gerber; Martin G Täuber; Philippe Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.